We are live on
!
Find out more
FFM
Fairmount Funds Management Portfolio holdings
AUM
$1.38B
1-Year Est. Return
407.79%
This Fund
S&P 500
This Quarter
Est. Return
+28.55%
1 Year Est. Return
+407.79%
3 Year Est. Return
+2,937.62%
5 Year Est. Return
+5,415.3%
10 Year Est. Return
–
AUM
$236M
AUM Growth
+$11.9M
(+5.3%)
Cap. Flow
+$23.2M
Cap. Flow
% of AUM
9.82%
Top 10 Holdings %
Top 10 Hldgs %
83.82%
Holding
17
New
3
Increased
8
Reduced
6
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cogent Biosciences
COGT
|
+$16.3M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$4.79M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
+$2.69M |
| 4 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$2.08M |
| 5 |
Insmed
INSM
|
+$1.32M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurogene
NGNE
|
+$4.81M |
| 2 |
ALLK
Allakos
ALLK
|
+$1.14M |
| 3 |
FOLD
Amicus Therapeutics
FOLD
|
+$729K |
| 4 |
Enanta Pharmaceuticals
ENTA
|
+$374K |
| 5 |
Iovance Biotherapeutics
IOVA
|
+$215K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Insmed
INSM
$23.5B
| $34M | 14.39% |
1,056,797
+46,000
| +5% | +$1.32M |
|
|
2
Acadia Pharmaceuticals
ACAD
$4.38B
| $26.7M | 11.32% |
647,833
+62,316
| +11% | +$2.69M |
|
|
TRIL
3
DELISTED
Trillium Therapeutics Inc.
TRIL
| $22.1M | 9.38% |
1,558,181
+75,000
| +5% | +$748K |
|
|
FOLD
4
DELISTED
Amicus Therapeutics
FOLD
| $20.6M | 8.7% |
1,455,395
-50,000
| -3% | -$729K |
|
|
5
Iovance Biotherapeutics
IOVA
$2.23B
| $19.6M | 8.32% |
596,890
-7,000
| -1% | -$215K |
|
|
ZGNX
6
DELISTED
Zogenix, Inc.
ZGNX
| $18.9M | 8.03% |
1,056,875
+85,000
| +9% | +$2.08M |
|
7
Axsome Therapeutics
AXSM
$11.8B
| $15.7M | 6.64% |
220,098
+4,000
| +2% | +$312K |
|
|
8
Cogent Biosciences
COGT
$6.68B
| $13.7M | 5.81% |
+1,558,976
| New | +$16.3M |
|
|
ALLK
9
DELISTED
Allakos
ALLK
| $13.4M | 5.68% |
164,662
-14,000
| -8% | -$1.14M |
|
10
argenx
ARGX
$53.8B
| $13.1M | 5.55% |
49,950
-500
| -1% | -$120K |
|
11
Karyopharm Therapeutics
KPTI
$216M
| $10.3M | 4.34% |
46,823
+3,333
| +8% | +$815K |
|
|
12
Enanta Pharmaceuticals
ENTA
$400M
| $7.43M | 3.15% |
162,236
-7,713
| -5% | -$374K |
|
|
AMRN
13
Amarin Corp
AMRN
$292M
| $6.35M | 2.69% |
75,412
+5,250
| +7% | +$629K |
|
|
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $5.81M | 2.46% |
+35,000
| New | +$4.79M |
|
|
15
Neurogene
NGNE
$744M
| $4.47M | 1.89% |
18,637
-19,867
| -52% | -$4.81M |
|
16
Kiniksa Pharmaceuticals
KNSA
$4.92B
| $3.26M | 1.38% |
212,746
+12,621
| +6% | +$237K |
|
|
VRNA
17
DELISTED
Verona Pharma
VRNA
| $624K | 0.26% |
+100,000
| New | +$691K |
|
Similar funds
NIP
OCAM
AU
RIM
VC
AO
1CP
OCM
Fairmount Funds Management's Q3 2020 Portfolio in Review
As of Q3 2020, Fairmount Funds Management held 17 positions worth $236M, up 5.3% from $224M the previous quarter. Its ten largest holdings account for 84% of the portfolio.
Fairmount Funds Management deployed $23.2M of net new capital in Q3 2020, opening 3 new positions and adding to 8 existing holdings. Its largest new stake was Cogent Biosciences: 1,558,976 shares worth $13.7M.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 95% a quarter earlier.
On the sell side, the largest reduction was Neurogene, an estimated $4.81M trimmed.
- Fairmount Funds Management's largest Q3 2020 buy was Cogent Biosciences: 1,558,976 shares worth $13.7M.
- Fairmount Funds Management added most to Acadia Pharmaceuticals in Q3 2020, an estimated $2.69M increase.
- Fairmount Funds Management's biggest Q3 2020 reduction was Neurogene, cutting an estimated $4.81M.
- Fairmount Funds Management's ten largest holdings make up 84% of its $236M portfolio in Q3 2020.
- Fairmount Funds Management opened 3 new positions and closed 0 in Q3 2020.
- Fairmount Funds Management's portfolio value rose 5.3% quarter-over-quarter to $236M.
Based on Fairmount Funds Management's 13F filing for Q3 2020, filed 12 Nov 2020.